ArticleNeuro-oncology advances

Prospective phase II trial of the dual mTORC1/2 inhibitor vistusertib for progressive or symptomatic meningiomas in persons with neurofibromatosis 2.

Justin T Jordan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.